Document Type

Article

Publication Date

3-7-2022

Comments

This article is the author’s final published version in IDCases, Volume 28, March 2022, Article number e01463.

The published version is available at https://doi.org/10.1016/j.idcr.2022.e01463. Copyright © Tsang, Haddad, and Sternlieb.

Abstract

Blastomycosis is an endemic mycosis in the United States that typically affects the respiratory tract and presents as a pneumonia. Dissemination can occur to any organ system, most commonly involving the skin or bones. Treatment of blastomycosis depends on the severity of disease and consists of itraconazole with liposomal amphotericin B added in during the initial stage in those with more severe disease or those who are pregnant. This case report describes an immunocompetent individual with mild to moderate blastomycosis of the larynx who was started on itraconazole therapy. However, after two months of treatment, he developed new symptomatic heart failure with reduced ejection fraction due to the itraconazole. His therapy was stopped after five months with improvement of his left ventricular ejection fraction days after discontinuation of therapy. He remained without relapse of disease after his abridged therapy duration.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

35308776

Language

English

Download

Included in

Cardiology Commons

Share

COinS